tradingkey.logo
搜尋

Telomir Pharmaceuticals Inc

TELO
添加自選
1.270USD
-0.030-2.31%
收盤 07/02, 13:00美東報價延遲15分鐘
43.66M總市值
虧損本益比TTM

關於 Telomir Pharmaceuticals Inc 公司

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.

Telomir Pharmaceuticals Inc簡介

公司代碼TELO
公司名稱Telomir Pharmaceuticals Inc
上市日期Feb 09, 2024
CEOAminov (Erez)
員工數量- -
證券類型Ordinary Share
年結日Feb 09
公司地址900 West Platt Street, Suite 200
城市TAMPA
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編33606
電話18138642562
網址https://telomirpharma.com/
公司代碼TELO
上市日期Feb 09, 2024
CEOAminov (Erez)

Telomir Pharmaceuticals Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.73M
+83.85%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
8.73M
+83.85%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--

常見問題

Telomir Pharmaceuticals Inc的前五大股東是誰?

Telomir Pharmaceuticals Inc的前五大股東如下:Mr. Erez Aminov

有多少機構持有Telomir Pharmaceuticals Inc(TELO)的股份?

截至2026Q1,共有110家機構持有Telomir Pharmaceuticals Inc的股份,合計持有的股份價值約為3.42M,占公司總股份的9.95% 。與2025Q4相比,機構持股有所增加,增幅為488600.00。